



Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness, Value, and Value-Based Price Benchmarks

Key Stakeholder Organizations

ICER has identified the following organizations as key stakeholders for its upcoming report on dupilumab and crisaborole for atopic dermatitis. ICER will invite input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER often receives comments from individual patients and clinicians, and invites the public to submit recommendations for key stakeholders in these categories.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- Asthma and Allergy Foundation of America
- National Eczema Association
- Prime Therapeutics
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc
- Sanofi S.A.
- International Eczema Council
- Anthem, Inc.
- Express Scripts